Founded by Yale University scholars and their team returning to China, HebaBiz Biotech is committed to creating personalized, precise and improved solutions for the treatment of cancers and liver diseases, guided by clinical value and patients' needs, and systematically improving the quality of traditional Chinese medicines by the use of cutting-edge biotechnology. Both of our Beijing and Guangxi entities are "National High-tech Enterprises" and our Beijing entity is a "Zhongguancun Hi-Tech Technology Enterprise" and our Guangxi entity is a "Specialized, Excellent, Featured and Innovative Enterprise".

HebaBiz Biotech has established a National & Local Joint Engineering Research Center for Anti-tumor Drug Development, systematic technology platforms for small-molecule drugs and innovative traditional Chinese medicines. HebaBiz Biotech has numerous international and domestic patented technologies, and seven new drug candidates in its pipeline under research and development, including China's Category 1.1 Anti-cancer Innovative Drug under the National New Drug Development Major Project. HebaBiz Biotech's pipeline is also strategically positioned to comprehensively cover liver disease indications including Liver Cancer, Chronic Hepatitis B virus, Nonalcoholic Steatohepatitis （NASH）, Alcoholic Liver Disease, weight, lipid and other metabolic disorders; at the same time, HebaBiz Biotech is seeking breakthroughs in Glioblastoma （GBM）, Pancreatic Cancer and Renal Cell Carcinoma etc.

In addition to small-molecule chemical drugs, HebaBiz Biotech is also committed to writing a new chapter of exploration on innovative multi-molecule and multi-target traditional Chinese medicines to solve chronic diseases, which is completely implemented in accordance with the international standard evaluation of CMC, preclinical pharmacodynamics and pharmacology, as well as clinical effectiveness, supplementing the disadvantage of many single target small-molecule drugs regarding the likelihood of missing the target(s) and may not effect a radical cure for chronic diseases. In this line, HebaBiz Biotech is hopeful in telling “a new China story”.

In parallel with innovative research and development, HebaBiz Biotech practices the principle of using the best from both Chinese and Western sources and implements a commercial layout of chemical medicines and natural medicines being mutually complementary. HebaBiz Biotech currently has a number of drug production lines, numerous product approvals; it has built and put into operation a modern production base of 68,000 square meters and has a productive sales team, and is strategically positioned as an full industry chain innovative pharmaceutical enterprise integrating research and development, production and sales.